- Molecular NameLomustine
- SynonymCCNU; Chloroethylcyclohexylnitrosourea; Lomustina [INN-Spanish]; Lomustinum [INN-Latin]
- Weight233.699
- Drugbank_IDDB01206
- ACS_NO13010-47-4
- Show 2D model
- LogP (experiment)2.629
- LogP (predicted, AB/LogP v2.0)2.51
- pkaN/A
- LogD (pH=7, predicted)2.51
- Solubility (experiment)0.111 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-2.63
- LogSw (predicted, AB/LogsW2.0)3.17
- Sw (mg/ml) (predicted, ACD/Labs)0.55
- No.of HBond Donors1
- No.of HBond Acceptors5
- No.of Rotatable Bonds4
- TPSA61.77
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn alkylating nitrosourea compound used in chemotherapy. It is in the same family as streptozotocin.
- Absorption_value100.0
- Absorption (description)Well and rapidly absorbed from the gastrointestinal tract.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding50.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic. Rapid and complete, with active metabolites.
- Half life94 min, however the metabolites have a serum half-life of 16 to 48 hours.
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityPulmonary toxicity has been reported at cumulative doses usually greater than 1,100 mg/m2. There is one report of pulmonary toxicity at a cumulative dose of only 600 mg. The onset of toxicity has varied from 6 months after initiation of therapy, to as late as 15 years after.
- LD50 (rat)LD50=70 mg/kg
- LD50 (mouse)LD50=30